ArticlePloS one2025
Novel Linalool-Silver nanoparticles: Synthesis, characterization, and dual approach evaluation via computational docking and antibacterial assays.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Activity of linalool based silver nanoconjugates against brain tumor through in silico, in vitro and in vivo evaluations.Scientific reports · 2026Article
- Correction: Linalool-based silver nanoconjugates as potential therapeutics for glioblastoma: in silico and in vitro insights.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, scientists have developed new medical delivery techniques based on nanotechnology and have been actively creating nanoparticles combined with various extracts from natural plant products. This study aimed to conjugate linalool surface with silver nanoparticles, investigate its characteristics, and evaluate its effectiveness as a possible new therapeutic target against bacterial strains. A CMC-linalool solution was used to create linalool-based AgNPs (LN@AgNPs), which were then characterized by UV-Vis, FTIR, SEM, DLS, and zeta potential studies. The shape, hydrodynamic diameter, and negative zeta potential were among the advantageous properties of the resultant particles, which improved their performance and stability. Antibacterial potential was assessed using both in silico and in vitro methods. According to molecular docking, LN@AgNPs exhibit strong interactions via hydrogen bonding and potential metallic chelation with important bacterial protein residues (Cys, His, and Thr). According to the in vitro assays, LN@AgNPs exhibited inhibitory zones comparable to those of azithromycin and stronger antibacterial efficacy than free linalool against Salmonella enterica, Bacillus subtilis, and Escherichia coli. According to these results, LN@AgNPs may be a good option for creating potent antimicrobial agents. To improve its therapeutic application, further investigation of its mode of action and in vivo safety profile is necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.